Barclays PLC Raises Stock Position in Repare Therapeutics Inc. (NASDAQ:RPTX)

Barclays PLC raised its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 1,471.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 8,330 shares of the company’s stock after buying an additional 7,800 shares during the quarter. Barclays PLC’s holdings in Repare Therapeutics were worth $29,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Stifel Financial Corp increased its stake in shares of Repare Therapeutics by 36.4% during the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after purchasing an additional 13,800 shares in the last quarter. Vontobel Holding Ltd. increased its stake in shares of Repare Therapeutics by 20.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after purchasing an additional 4,000 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Repare Therapeutics by 21.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after purchasing an additional 8,809 shares in the last quarter. Blue Owl Capital Holdings LP increased its stake in shares of Repare Therapeutics by 8.0% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock worth $11,129,000 after purchasing an additional 250,000 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in shares of Repare Therapeutics by 428.4% during the 2nd quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock worth $472,000 after purchasing an additional 115,916 shares in the last quarter. 85.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RPTX. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a research note on Friday, November 8th. Stifel Nicolaus lowered their target price on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, Lifesci Capital reaffirmed a “market perform” rating on shares of Repare Therapeutics in a research note on Friday, December 13th.

Repare Therapeutics Stock Performance

RPTX stock opened at $1.38 on Friday. The stock has a market capitalization of $58.67 million, a P/E ratio of -0.69 and a beta of 0.88. Repare Therapeutics Inc. has a one year low of $1.20 and a one year high of $8.49. The company has a 50 day moving average price of $2.47 and a two-hundred day moving average price of $3.03.

Repare Therapeutics Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.